secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xencor Inc (XNCR)
CIK:        0001326732
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001326732-26-000002
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xencor reports $611M cash; outlines 2026 pipeline milestones for XmAb candidates
--------------------------------------------------------------------------------

- Unaudited cash, equivalents & marketable debt securities ~$611M as of Dec 31, 2025 vs $706.7M a year ago.
- Cash expected to fund operations through 2028 based on current plans.
- XmAb819 (ENPP3xCD3) for ccRCC: 25% partial response; pivotal study planned in 2027.
- XmAb541 (CLDN6xCD3) for gynecologic/germ cell tumors: confirmed partial responses in 3 of 9 patients; pivotal study planned in 2027.
- Autoimmune pipeline: Phase 1b plamotamab in RA, Phase 1 XmAb657 in IIM, Phase 2b XENITH-UC, and first-in-human TL1AxIL23p19 in 2H26.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326732/000132673226000002/0001326732-26-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326732/000132673226000002/xncr-20260108.htm
  HTML page:      https://secwatch.observer/filing/0001326732-26-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer